How to buy Agios Pharmaceuticals stock | $44.28

Agios Pharmaceuticals Inc is a biotechnology business based in the US. Agios Pharmaceuticals shares (AGIO) are listed on the NASDAQ and all prices are listed in US Dollars. Agios Pharmaceuticals employs 562 staff and has a trailing 12-month revenue of around 0.00.

Agios Pharmaceuticals stock price (NASDAQ: AGIO)

Use our graph to track the performance of AGIO stocks over time.

Agios Pharmaceuticals shares at a glance

• Key figures

Information last updated 2021-10-16.

Latest market close	$44.28
52-week range	$32.47 - $62.16
50-day moving average	$45.76
200-day moving average	$51.51
Wall St. target price	$62.43
PE ratio	1.9555
Dividend yield	N/A (0%)
Earnings per share (TTM)	$23.67

Buy Agios Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Agios Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Agios Pharmaceuticals price performance over time

Historical closes compared with the close of $44.28 from 2021-10-18

1 week (2021-10-08)	N/A
1 month (2021-09-17)	-6.07%
3 months (2021-07-19)	-21.38%
6 months (2021-04-19)	-18.77%

1 year (2020-10-19)	25.51%
2 years (2019-10-18)	33.90%
3 years (2018-10-19)	66.88
5 years (2016-10-19)	48.32

Is Agios Pharmaceuticals under- or over-valued?

Valuing Agios Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Agios Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Agios Pharmaceuticals's P/E ratio

Agios Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 2x. In other words, Agios Pharmaceuticals shares trade at around 2x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Agios Pharmaceuticals financials

Revenue TTM	$203.2 million
Gross profit TTM	$-167,079,000
Return on assets TTM	-14.4%
Return on equity TTM	-29.42%
Profit margin	783.22%
Book value	$28.74
Market capitalisation	$2.7 billion

TTM: trailing 12 months

Shorting Agios Pharmaceuticals shares

There are currently 6.2 million Agios Pharmaceuticals shares held short by investors – that's known as Agios Pharmaceuticals's "short interest". This figure is 8.6% up from 5.7 million last month.

There are a few different ways that this level of interest in shorting Agios Pharmaceuticals shares can be evaluated.

Agios Pharmaceuticals's "short interest ratio" (SIR)

Agios Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Agios Pharmaceuticals shares currently shorted divided by the average quantity of Agios Pharmaceuticals shares traded daily (recently around 411083.52084712). Agios Pharmaceuticals's SIR currently stands at 15.11. In other words for every 100,000 Agios Pharmaceuticals shares traded daily on the market, roughly 15110 shares are currently held short.

However Agios Pharmaceuticals's short interest can also be evaluated against the total number of Agios Pharmaceuticals shares, or, against the total number of tradable Agios Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Agios Pharmaceuticals's short interest could be expressed as 0.11% of the outstanding shares (for every 100,000 Agios Pharmaceuticals shares in existence, roughly 110 shares are currently held short) or 0.1066% of the tradable shares (for every 100,000 tradable Agios Pharmaceuticals shares, roughly 107 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Agios Pharmaceuticals.

Find out more about how you can short Agios Pharmaceuticals stock.

Agios Pharmaceuticals share dividends

We're not expecting Agios Pharmaceuticals to pay a dividend over the next 12 months.

Agios Pharmaceuticals share price volatility

Over the last 12 months, Agios Pharmaceuticals's shares have ranged in value from as little as $32.47 up to $62.16. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Agios Pharmaceuticals's is 1.5624. This would suggest that Agios Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Agios Pharmaceuticals overview

Agios Pharmaceuticals, Inc. , a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA (enasidenib), an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat IC eligible frontline AML; that is in Phase III clinical trials for treating IC ineligible frontline AML; and that is in Phase III clinical trials for the treatment of cholangiocarcinoma, as well as in early stage clinical development to treat glioma and solid tumors. In addition, the company is developing IDHIFA, which has completed Phase II clinical study for treating IC eligible frontline AML; and that is in Phase I/II clinical trials for the treatment of IC ineligible frontline AML. Further, it is developing mitapivat, which is in Phase III clinical trials to treat pyruvate kinase deficiency, as well as in Phase II clinical study for treating thalassemia and sickle cell disease; vorasidenib (AG-881) that is in Phase I clinical trials for the treatment of solid tumors, including glioma; AG-270, which is in Phase I dose-escalation trial to treat methylthioadenosine phosphorylase deleted tumors; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc.

Frequently asked questions

What percentage of Agios Pharmaceuticals is owned by insiders or institutions?
Currently 1.086% of Agios Pharmaceuticals shares are held by insiders and 113.233% by institutions. How many people work for Agios Pharmaceuticals?
Latest data suggests 562 work at Agios Pharmaceuticals. When does the fiscal year end for Agios Pharmaceuticals?
Agios Pharmaceuticals's fiscal year ends in December. Where is Agios Pharmaceuticals based?
Agios Pharmaceuticals's address is: 88 Sidney Street, Cambridge, MA, United States, 02139-4169 What is Agios Pharmaceuticals's ISIN number?
Agios Pharmaceuticals's international securities identification number is: US00847X1046 What is Agios Pharmaceuticals's CUSIP number?
Agios Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 00847X104